TKNO
Alpha Teknova, Inc.
Key Financials
EPS (Diluted)
$-0.32
↑ 43.9%
Net Income
$-17259000
↑ 35.5%
Revenue
$40.5M
↑ 7.4%
Gross Profit
$13.4M
↑ 85.9%
Total Assets
$103.6M
↓ 12.8%
Total Liabilities
$34.8M
↓ 4.3%
Shareholders' Equity
$68.8M
↓ 16.5%
Cash & Equivalents
$5.9M
↑ 59.4%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
| 8-K | 6/1/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/6/2026 | View on SEC |
| ARS | 4/21/2026 | View on SEC |
| DEFA14A | 4/21/2026 | View on SEC |
| DEF 14A | 4/21/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TKNO |
| Company Name | Alpha Teknova, Inc. |
| CIK | 1850902 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 8316371100 |